You are here:  Home  >  Biotech  >  Current Article

GT Biopharma developing treatment for coronavirus

By   /   Tuesday, March 10th, 2020  /   No Comments

    Print       Email
Westlake Village drug developer GT Biopharma announced a collaboration with the U.S.-based subsidiary of a Chinese company to produce and test its TriKE therapeutic platform to treat patients infected with the novel coronavirus. Cytovance Biologics, a subsidiary of Shenzhen Hepalink Pharmaceutical, will manufacture GT Biopharma’s drug for preclinical evaluation and could later scale up production…


    This article is only available to Business Times subscribers
  • Subscribers: LOG IN or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email

Leave a Reply

Your email address will not be published. Required fields are marked *

You might also like...

Tri-county hospital rebuilds make room for beds

Read More →